Compound I Crystal Forms for Stable HCV Inhibitor Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, such as peginterferon-alpha combined with ribavirin, suffer from substantial limitations in efficacy and tolerability, with inadequate viral elimination and significant side effects, necessitating the development of new drugs.
Innovation Solution
Development of crystalline polymorphs of Compound I, a potent HCV protease inhibitor, which modulates physicochemical properties like solubility, stability, and crystallization characteristics, enhancing pharmaceutical properties and providing improved formulations for drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If amorphous or liquid forms of Compound I are used, then flexibility in formulation is improved, but physical stability and shelf life deteriorate due to hygroscopicity and crystallization upon storage
Solution Approach 1:
The patent applies parameter changes by transforming Compound I from amorphous/liquid states to specific crystalline forms (Forms A, B, C, D, E) with defined molecular arrangements. This phase transition from disordered to ordered states fundamentally changes the physical parameters including density, melting point, and hygroscopicity, thereby achieving both formulation flexibility and enhanced physical stability.
Solution Approach 2:
The invention directly utilizes phase transitions by isolating and characterizing multiple crystalline polymorphs of Compound I. Each crystalline form represents a distinct phase with specific lattice structures that provide different stability profiles. The transition from amorphous/liquid phases to crystalline phases eliminates hygroscopicity while maintaining formulation adaptability through selection of appropriate polymorphs.
2Reliability
If multiple polymorphs are discovered and characterized, then understanding of stability relationships is improved, but complexity of characterization and differentiation increases
Solution Approach 1:
The patent applies segmentation by dividing the complex polymorph characterization into distinct, identifiable crystalline forms (A, B, C, D, E), each with unique PXRD patterns. This segmentation allows systematic differentiation and identification of each polymorph through specific characteristic peaks, simplifying the overall characterization process despite the presence of multiple forms.
Solution Approach 2:
The invention utilizes PXRD pattern variations as a 'fingerprint' system for differentiating polymorphs. Each crystalline form exhibits distinct diffraction peak positions and intensities, analogous to color changes, providing a reliable and simple method for polymorph identification and stability assessment without complex analytical procedures.
3Stability of the object's composition
If crystalline forms with specific PXRD patterns are developed, then physical stability is improved, but difficulty in detecting and measuring specific crystal forms increases
Solution Approach 1:
The patent transforms the detection challenge into a simplified identification process by establishing unique PXRD 'fingerprints' for each crystalline form. The characteristic peak positions and intensities serve as identifiable markers, making crystal form detection straightforward through routine powder diffraction analysis rather than complex characterization methods.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of Figures 1-4.